The AVYIA Journal
All Articles · Page 3
The latest ketamine research explained in plain language, real patient case studies, and practical guides for your mental health.
Archive
Page 3 of 7
Ketamine Infusion Study in Patients with Comorbid PTSD and TRD: Remarkable Remission Rates
New study finds ketamine infusions yield 80% PTSD remission and 93% depression response in patients with comorbid TRD—offering rapid, life-changing relief.
Narrative Review: Ketamine as an Adjunct Treatment for PTSD
Narrative review confirms ketamine’s value as an adjunct for PTSD, helping improve therapy response, emotional regulation, and long-term symptom relief.
Ketamine for PTSD: Meta-Analysis Shows Promising Symptom Relief
New meta-analysis shows ketamine offers fast and effective symptom relief for PTSD, with benefits emerging within 24 hours and lasting several days post-infusion.
Safe, Low-Cost Ketamine: A Promising Treatment for Severe Depression
Clinical trials show that low-cost ketamine is a safe, fast, and effective treatment for severe depression—offering rapid relief and expanding global access.
KADS Trial: Subcutaneous Ketamine Proves Effective for Treatment-Resistant Depression
The KADS trial shows subcutaneous ketamine is a safe, fast, and effective option for treatment-resistant depression—offering new hope and easier access.
UNSW Low-Cost Ketamine Trial: A Game Changer for Depression Treatment
The UNSW ketamine trial shows that generic, low-cost ketamine is safe and effective for treating depression. A breakthrough for affordable global mental health care.
Racemic Ketamine for Depression: What 49 Clinical Trials Reveal About Its Effectiveness and Safety
Learn how racemic ketamine helps treat depression. Discover findings from 49 clinical trials on safety, effectiveness, and real-world results.
Ketamine’s Antidepressant Efficacy in MDD and Bipolar Depression: A Meta-Analytic Review
Meta-analysis confirms ketamine’s fast, lasting antidepressant effects in MDD and bipolar depression, with benefits seen in just 24 hours.
Ketamine Shows Dose-Dependent Relief for Refractory Anxiety Disorders
Ketamine reduces anxiety within 1 hour, lasting up to 7 days, with dose-dependent effects in treatment-resistant GAD and SAD patients.
Extending Ketamine’s Reach: Can Exposure-Based CBT Sustain Obsessive-Compulsive Disorder Relief?
Combining ketamine with exposure-based CBT may help sustain OCD symptom relief, per a 2016 open-label trial by Rodriguez et al.
Restoring Calm: Maintenance Ketamine Therapy Offers Hope for Severe Anxiety Disorders
Weekly ketamine injections offer lasting anxiety relief in GAD and SAD patients resistant to traditional therapies, with minimal side effects.
Dual Relief in Focus: Repeated Ketamine Infusions Ease PTSD and Depression Symptoms
Repeated ketamine infusions significantly reduce PTSD and depression symptoms in patients unresponsive to standard treatments.
OnlineTalk to ProviderCall us